RBP4 and Stargardt disease: Tinlarebant, an oral retinol-binding protein 4 (RBP4) inhibitor currently undergoing phase III testing in the DRAGON trial, has received FDA Breakthrough Therapy designation for Stargardt disease (STGD1) due to its ability to limit retinoid flux to the retina [180].